Document is current
Any future updates will be listed below
-
Authors
Fox, Thomas https://orcid.org/0000-0002-1163-2295
Bueren, Juan https://orcid.org/0000-0002-3228-7013
Candotti, Fabio https://orcid.org/0000-0001-6399-6042
Fischer, Alain https://orcid.org/0000-0003-4025-5983
Aiuti, Alessandro https://orcid.org/0000-0002-5398-1717
Lankester, Arjan
,
Albert, Michael
Bernardo, Maria Ester
Cavazzana, Marina
Ehl, Stephan
Neven, Benedicte
Prevot, Johan
Schambach, Axel
Sevilla, Julian
Thrasher, Adrian
Wynn, Rob
Booth, Claire
- License Information
-
More Information
Article History
First Online: 13 February 2023
Competing interests
: J.B. is a consultant to and has licensed advanced therapy medicinal products to Rocket Pharma. A.A. is principal investigator of clinical trials sponsored by Orchard Therapeutics, which has licensed gene therapy products for ADA-SCID, Wiskott-Aldrich syndrome, metachromatic leukodystrophy, β-thalassemia and mucopolysaccharidosis type I, originally developed at SR-Tiget, and is a member of the Committee for Advanced Therapies; his views are personal and may not be understood or quoted as being made on behalf of the European Medicines Agency. A.L. is principal investigator of an academic clinical trial for RAG-1 SCID with a licensing agreement to Mustang Bio. C.B. is an investigator of clinical trials sponsored by Rocket Pharma, Bluebird Bio, AvroBio and previously Orchard Therapeutics in addition to academic clinical trials.
